You are about to leave the Clinical Value website now.

Cancel

Impact of PIVKA-II in diagnosis of hepatocellular carcinoma

Quick Summary

Liver cancer grows silently with mild or no symptoms until advanced. In the absence of an effective treatment for advanced stage of hepatic cancer hope lies in early detection, and screening for high-risk population. Among Egyptians viral hepatitis is the most common risk factor for hepatocellular carcinoma (HCC).

This study was designed to determine the level of prothrombin induced by vitamin K absence-II (PIVKA-II) in sera of patients suffering from HCC to diagnose HCC at its early stage.

PIVKA-II proved to be superior to AFP for early detection of HCC patients being highly sensitive and specific. Furthermore it has the ability to discriminate between different histopathological grades of HCC and It has a powerful diagnostic validity to evaluate the thrombosis of portal vein and to differentiate between early and late stages of HCC. The direct relation between the level of PIVKA-II and the size of tumor makes it an attractive tool for early HCC diagnosis and surveillance. Using the best cut-off value of AFP (>28), showed a sensitivity of (44%) and specificity of (73.3%). While cut-off value of PIVKA-II (>53.7) showed 100% sensitivity and specificity.

Authors: Nadia I. Zakhary, Sherif M. Khodeer, Hanan E. Shafik, Camelia A. Abdel Malak

You May Also Like

13 September 2024

Empowering Precision Oncology: Leveraging digital solutions to facilitate molecular tumour board meetings and patient care management

Read More
19 August 2024

Pioneering Innovations in HCC Detection for Enhance Patient Outcomes – Chang Gung Memorial Hospital

Read More
19 August 2024

Strategic Efficiencies: Evaluating Cost-Effectiveness of Biomarker-Based HCC Surveillance

Read More

SHARE

Be the first to receive updates, event opportunities, and thought leadership insights.